{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:36:45Z","timestamp":1787726205771,"version":"build-2784847793"},"reference-count":38,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR132948"],"award-info":[{"award-number":["NIHR132948"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title>\n<jats:p>Proliferative diabetic retinopathy is a major cause of sight loss in people with diabetes, with a high risk of vitreous haemorrhage, tractional retinal detachment and other complications. Panretinal photocoagulation is the primary established treatment for proliferative diabetic retinopathy. Anti-vascular endothelial growth factor drugs are used to treat various eye conditions and may be beneficial for people with proliferative diabetic retinopathy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-2\"><jats:title>Objective<\/jats:title>\n<jats:p>To investigate the efficacy and safety of anti-vascular endothelial growth factor therapy for the treatment of proliferative diabetic retinopathy when compared to panretinal photocoagulation.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-3\"><jats:title>Methods<\/jats:title>\n<jats:p>A systematic review and network meta-analysis of randomised controlled trials comparing anti-vascular endothelial growth factor (alone or in combination) to panretinal photocoagulation in people with proliferative diabetic retinopathy. The database searches were updated in May 2023. Trials where the primary focus was treatment of macular oedema or vitreous haemorrhage were excluded. Key outcomes were best corrected visual acuity, diabetic macular oedema and vitreous haemorrhage. Individual participant data were obtained and analysed for three large, high-quality trials in combination with published data from other trials. Network meta-analyses of best corrected visual acuity and meta-analyses of other outcomes combined individual participant data with published data from other trials; regression analyses against patient covariates used just the individual participant data.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-4\"><jats:title>Results<\/jats:title>\n<jats:p>Twelve trials were included: one of aflibercept, five of bevacizumab and six of ranibizumab. Individual participant data were available from 1 aflibercept and 2 ranibizumab trials, representing 624 patients (33% of the total).<\/jats:p>\n<jats:p>When considered together, anti-vascular endothelial growth factors produced a modest, but not clinically meaningful, benefit over panretinal photocoagulation in best corrected visual acuity, after 1 year of follow-up (mean difference in logarithm of the minimum angle of resolution \u22120.116, 95% credible interval \u22120.183 to \u22120.038). There was no clear evidence of a difference in effectiveness between the anti-vascular endothelial growth factors. The benefit of anti-vascular endothelial growth factor appears to decline over time. Analysis of the individual participant data trials suggested that anti-vascular endothelial growth factor therapy may be more effective in people with poorer visual acuity, in those who have vitreous haemorrhage and, possibly, in people with poorer vision generally.<\/jats:p>\n<jats:p>Anti-vascular endothelial growth factor was superior to panretinal photocoagulation at preventing macular oedema after 1 year (relative risk 0.48, 95% confidence interval 0.28 to 0.83) and possibly at preventing vitreous haemorrhage (relative risk 0.72, 95% confidence interval 0.47 to 1.10). Anti-vascular endothelial growth factor reduced the incidence of retinal detachment when compared to panretinal photocoagulation (relative risk 0.41, 95% confidence interval 0.22 to 0.77). Data on other adverse events were generally too limited to identify any differences between anti-vascular endothelial growth factor and panretinal photocoagulation.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-5\"><jats:title>Conclusions<\/jats:title>\n<jats:p>Anti-vascular endothelial growth factor has no clinically meaningful benefit over panretinal photocoagulation for preserving visual acuity. However, anti-vascular endothelial growth factor therapy appears to delay or prevent progression to macular oedema and vitreous haemorrhage. The possibility that anti-vascular endothelial growth factor therapy may be more effective in patients with poorer health and poorer vision merits further clinical investigation. The long-term effectiveness and safety of anti-vascular endothelial growth factor treatment are unclear, particularly as additional panretinal photocoagulation and anti-vascular endothelial growth factor treatment will be required over time.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-6\"><jats:title>Funding<\/jats:title>\n<jats:p>This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR132948.<\/jats:p>\n<\/jats:sec>","DOI":"10.3310\/mjyp6578","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:42:40Z","timestamp":1724838160000},"page":"1-75","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-8515","authenticated-orcid":true,"given":"Mark","family":"Simmonds","sequence":"first","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-5136","authenticated-orcid":true,"given":"Alexis","family":"Llewellyn","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-7363","authenticated-orcid":true,"given":"Ruth","family":"Walker","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-1099","authenticated-orcid":true,"given":"Helen","family":"Fulbright","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-3689","authenticated-orcid":true,"given":"Matthew","family":"Walton","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-2893","authenticated-orcid":true,"given":"Rob","family":"Hodgson","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-9109","authenticated-orcid":true,"given":"Laura","family":"Bojke","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-4724","authenticated-orcid":true,"given":"Lesley","family":"Stewart","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-0221","authenticated-orcid":true,"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rush","sequence":"additional","affiliation":[{"name":"Patient Representative, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-8521","authenticated-orcid":true,"given":"Jo\u00e3o Pereira","family":"Figueira","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Coimbra, Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-0659","authenticated-orcid":true,"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2031-6390","authenticated-orcid":true,"given":"John G","family":"Lawrenson","sequence":"additional","affiliation":[{"name":"Department of Optometry and Visual Sciences, City University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-0381","authenticated-orcid":true,"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-3089","authenticated-orcid":true,"given":"David","family":"Steel","sequence":"additional","affiliation":[{"name":"Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2025,4]]},"reference":[{"key":"key2025061712255900_ref1-bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/eye.2012.287","article-title":"The Royal College of Ophthalmologists\u2019 clinical guidelines for diabetic retinopathy: a summary","volume":"27","author":"Ghanchi","year":"2013","journal-title":"Eye"},{"key":"key2025061712255900_ref2-bib2","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.ophtha.2008.08.023","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy: xxii the twenty-five-year progression of retinopathy in persons with type 1 diabetes","volume":"115","author":"Klein","year":"2008","journal-title":"Ophthalmology"},{"key":"key2025061712255900_ref3-bib3","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/s2214-109x(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"key2025061712255900_ref4-bib4","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/archopht.1979.01020010310003","article-title":"Four risk factors for severe visual loss in diabetic retinopathy. The third report from the diabetic retinopathy study. The diabetic retinopathy study research group","volume":"97","author":"The Diabetic Retinopathy Study Research Group","year":"1979","journal-title":"Arch Ophthalmol"},{"key":"key2025061712255900_ref5-bib5","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1097\/IAE.0000000000000192","article-title":"Ocular findings at initial pan retinal photocoagulation for proliferative diabetic retinopathy predict the need for future pars plana vitrectomy","volume":"34","author":"Parikh","year":"2014","journal-title":"Retina"},{"key":"key2025061712255900_ref6-bib6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0161-6420(13)38014-2","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"key":"key2025061712255900_ref7-bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19510","article-title":"Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation","volume":"19","author":"Royle","year":"2015","journal-title":"Health Technol Assess"},{"key":"key2025061712255900_ref8-bib8","volume-title":"Ranibizumab for Treating Diabetic Macular Oedema","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key2025061712255900_ref9-bib9","volume-title":"Aflibercept for Treating Diabetic Macular Oedema","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key2025061712255900_ref10-bib10","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","article-title":"Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: Results from the panorama randomized clinical trial","volume":"139","author":"Brown","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"key2025061712255900_ref11-bib11","volume-title":"Anti-VEGF Treatment. RNIB","author":"Royal National Institute of Blind People (RNIB)"},{"key":"key2025061712255900_ref12-bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajo.2019.03.005","article-title":"Anti-vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions","volume":"204","author":"Wubben","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"key2025061712255900_ref13-bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","article-title":"Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor","volume":"126","author":"Obeid","year":"2019","journal-title":"Ophthalmology"},{"key":"key2025061712255900_ref14-bib14","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","article-title":"Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings","volume":"125","author":"Wong","year":"2018","journal-title":"Ophthalmology"},{"key":"key2025061712255900_ref15-bib15","volume-title":"Diabetic Retinopathy (Guidance in Development)","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2025061712255900_ref16-bib16","article-title":"Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis","author":"Simmonds","year":"2023","journal-title":"NIHR J Lib"},{"key":"key2025061712255900_ref17-bib17","volume-title":"Systematic Reviews: CRD\u2019s Guidance for Undertaking Reviews in Health Care","author":"Centre for Reviews and Dissemination"},{"key":"key2025061712255900_ref18-bib18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"key2025061712255900_ref19-bib19","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key2025061712255900_ref20-bib20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/rssa.12579","article-title":"Multilevel network meta-regression for population-adjusted treatment comparisons","volume":"183","author":"Phillippo","year":"2020","journal-title":"J Royal Statistical Soc Series A"},{"key":"key2025061712255900_ref21-bib21","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7326\/M18-3542","article-title":"Threshold analysis as an alternative to grade for assessing confidence in guideline recommendations based on network meta-analyses","volume":"170","author":"Phillippo","year":"2019","journal-title":"Ann Intern Med"},{"key":"key2025061712255900_ref22-bib22","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (clarity): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"key2025061712255900_ref23-bib23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ophtha.2017.12.008","article-title":"Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (proteus study)","volume":"125","author":"Figueira","year":"2018","journal-title":"Ophthalmology"},{"key":"key2025061712255900_ref24-bib24","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"key2025061712255900_ref25-bib25","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1111\/aos.14312","article-title":"Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy \u2013 the pride study","volume":"98","author":"Lang","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"key2025061712255900_ref26-bib26","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamaophthalmol.2021.0606","article-title":"Effect of intravitreous anti\u2013vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol W randomized clinical trial","volume":"139","author":"Maturi","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"key2025061712255900_ref27-bib27","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1097\/IAE.0000000000002377","article-title":"Photocoagulation versus ranibizumab for proliferative diabetic retinopathy: should baseline characteristics affect choice of treatment?","volume":"39","author":"Bressler","year":"2019","journal-title":"Retina"},{"key":"key2025061712255900_ref28-bib28","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jama.2019.0265","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"321","author":"Gross","year":"2019","journal-title":"JAMA"},{"key":"key2025061712255900_ref29-bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/IAE.0000000000000363","article-title":"A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy","volume":"35","author":"Ferraz","year":"2015","journal-title":"Retina"},{"key":"key2025061712255900_ref30-bib30","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1111\/j.1755-3768.2011.02184.x","article-title":"Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy","volume":"89","author":"Filho","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"key2025061712255900_ref31-bib31","first-page":"30","article-title":"Retinal function in proliferative diabetic retinopathy treated with intravitreal ranibizumab and laser photocoagulation targeted to ischemic retina","volume":"136","author":"Messias","year":"2018","journal-title":"Doc Ophthalmol"},{"key":"key2025061712255900_ref32-bib32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.15406\/aovs.2017.07.00211","article-title":"Panretinal photocoagulation versus intravitreal bevacizumab for proliferative diabetic retinopathy treatment","volume":"7","author":"Marashi","year":"2017","journal-title":"Adv Ophthalmol Visual System"},{"key":"key2025061712255900_ref33-bib33","first-page":"10","article-title":"Comparison between panretinal photocoagulation and panretinal photocoagulation plus intravitreal bevacizumab in proliferative diabetic retinopathy","volume":"24","author":"Ahmad","year":"2012","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"key2025061712255900_ref34-bib34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.29271\/jcpsp.2018.12.923","article-title":"Panretinal photocoagulation plus intravitreal bevacizumab versus panretinal photocoagulation alone for proliferative diabetic retinopathy","volume":"28","author":"Ali","year":"2018","journal-title":"J Coll Physicians Surg Pak"},{"key":"key2025061712255900_ref35-bib35","first-page":"157","article-title":"Comparison of efficacy of combination therapy of an intravitreal injection of bevacizumab and photocoagulation versus pan retinal photocoagulation alone in high risk proliferative diabetic retinopathy","volume":"37","author":"Shaikh","year":"2021","journal-title":"Pak J Med Sci"},{"key":"key2025061712255900_ref36-bib36","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1097\/IAE.0000000000001027","article-title":"Choroidal thickness changes in proliferative diabetic retinopathy treated with panretinal photocoagulation versus panretinal photocoagulation with intravitreal bevacizumab","volume":"36","author":"Roohipoor","year":"2016","journal-title":"Retina"},{"key":"key2025061712255900_ref37-bib37","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1167\/iovs.02-110","article-title":"How sensitive to clinical change are ETDRS logMAR visual acuity measurements?","volume":"44","author":"Rosser","year":"2003","journal-title":"Investig Opthalmol Visual Sci"},{"key":"key2025061712255900_ref38-bib38","volume-title":"Official Statistics: Public Health Outcomes Framework \u2013 Statistical Commentary","author":"Public Health England","year":"2020"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/MJYP6578\/MJYP6578.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T07:16:14Z","timestamp":1750144574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/published-articles\/MJYP6578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":38,"alternative-id":["10.3310\/MJYP6578"],"URL":"https:\/\/doi.org\/10.3310\/mjyp6578","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"08-2021","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"11-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"08-2024","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}